Literature DB >> 23712182

Chemotherapy: Maintenance therapy in breast cancer--many questions remain.

Miguel Martín1, Sara López-Tarruella.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23712182     DOI： 10.1038/nrclinonc.2013.87

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.

Authors:  Gianfilippo Bertelli; Ornella Garrone; Laura Bertolotti; Marcella Occelli; Serafino Conforti; Nicola Marzano; Antonio Febbraro; Paolo Carlini; Christina Liossi; Lucia Del Mastro; Robert C F Leonard
Journal:  Oncology       Date:  2005-07-11       Impact factor: 2.935

2.  Detecting an overall survival benefit that is derived from progression-free survival.

Authors:  Kristine R Broglio; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

3.  The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?

Authors:  Andrew D Seidman
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

4.  Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

Authors:  Emilio Alba; Manuel Ruiz-Borrego; Mireia Margelí; Alvaro Rodríguez-Lescure; Pedro Sánchez-Rovira; Amparo Ruiz; Jose Ramón Mel-Lorenzo; Manuel Ramos-Vázquez; Nuria Ribelles; Elisa Calvo; Antonio Casado; Antonia Márquez; David Vicente; José Angel García-Sáenz; Miguel Martín
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

5.  Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.

Authors:  Alessandra Gennari; Dino Amadori; Mario De Lena; Oriana Nanni; Paolo Bruzzi; Vito Lorusso; Luigi Manzione; Pier Franco Conte
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

6.  Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.

Authors:  Yeon Hee Park; Kyung Hae Jung; Seock-Ah Im; Joo Hyuk Sohn; Jungsil Ro; Jin-Hee Ahn; Sung-Bae Kim; Byung-Ho Nam; Do Youn Oh; Sae-Won Han; Soohyeon Lee; In Hae Park; Keun Seok Lee; Jee Hyun Kim; Seok Yun Kang; Moon Hee Lee; Hee Sook Park; Jin Seok Ahn; Young-Hyuck Im
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

7.  Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer.

Authors:  Armelle Dufresne; Xavier Pivot; Christophe Tournigand; Thomas Facchini; Thierry Alweeg; Loic Chaigneau; Aimery De Gramont
Journal:  Int J Med Sci       Date:  2008-05-05       Impact factor: 3.738
  7 in total
  1 in total

1.  First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients.

Authors:  Xu Liang; Ying Yan; Lina Wang; Guohong Song; Lijun DI; Hanfang Jiang; Chaoying Wang; Huiping Li
Journal:  Oncol Lett       Date:  2014-12-10       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.